Novo Nordisk On Saturday, he said his diabetes pill Rybelsus showed cardiovascular benefits in a late -stage test, running the way to become a new treatment option for people living with diabetes and heart disease.
The pill reduced the risk of death associated with cardiovascular disease, heart attack and stroke by 14% compared to placebo after four years on average in patients with diabetes and established heart disease, with or without chronic kidney disease. Danish drug manufacturer presented the results at Rybelsus, which has already been approved for type 2 diabetes, on the annual scientific session of the American College of Cardiology in Chicago.
Novo Nordisk has already applied to the United States -UI to expand the pill approval to include a reduction in the risk of serious cardiovascular complications, said the Growth, Global Medical Director of the Company.
Rybelsus is an oral formulation of newborn Nordic diabetes injection of omempic, which is taken once a week. Both treatments, as well as a company that weekly injection of weight loss, contain an active ingredient in semaglutides.
Wegovy in March 2024 won us the approval to reduce the risk of major cardiovascular events in adults with cardiovascular disease and who were obese or excessively. However, the data on tablets presented on Saturday suggests that patients who hesitate to take injections, such as the ones who are afraid of the needle, could soon approach treatment in a more appropriate way.
“We know everyone does not want an injection, whether it’s painful or not, they want an oral drug,” Gough told CNBC. “We allow this possibility that you can have one or the other, depending on what patients and healthcare professionals think is that there is a common discussion.”
Data come as a panel of other drug manufacturers including Eli Lilly, Work on the development of oral GLP-1 for diabetes, weight loss and other conditions, such as apnea in a dream.
The third phase test examined just over 9,600 patients 50 years and older who received either Rybelsus or Placebo, both at the top of their standard treatment regime, on average just under four years. Almost half of all patients received medicines called SGLT2 inhibitors, which are primarily used to lower blood sugar in adults with type 2 diabetes, at some point during testing.
At the end of the trial, 12% of the people who took Rybelsus and 13.8% of those who took placebo experienced death, heart attack or stroke. This represents 14% of the total lower risk among those who took Rybelsus.
Researchers have said that the reduced risk is in accordance with the cardiovascular advantages observed in eight previous trials that included injectable GLP-1, which include semaglutide and other popular medicines, according to a statement from the American Faculty of Cardiology. GLP-1S imitate certain hormones of the gut to conceal the appetite and regulate blood sugar, but also have other effects such as reduction of inflammation.
Rybelsus helped to reduce the risk of non -fabulous heart attacks by 26% compared to placebo, which was the “main driver” of the total reduction in the risk of cardiovascular complications in the trial, the statement said. The pill also reduced the risk of non -fabulous 12% and cardiovascular deaths by 7% compared to placebo.
There were no significant differences between Rybelsus and a placebo group in the outcomes relating to the kidney function, the edition was added. But the trial was “clearly” intended for the testing of cardiovascular, not the kidney advantages of the tablet, Gough said.
The ground is Already approved For the treatment of chronic kidney disease in patients with diabetes.
The most common side effects reported in the study were gastrointestinal issues, such as nausea, diarrhea and constipation, which rarely brought in patients to stop taking Rybelsus, the statement said. These symptoms are in line with the side effects of semaglutide that can be injected.
Similar results have been reported in all patients subgroups – according to age, gender and among persons with different health conditions at the beginning of the test, according to a statement.
Unlike its injection colleagues, Rybelsus must be taken on an empty stomach at least 30 minutes before breakfast with a small amount of water. Despite these demands, the study offers “persuasion that patients have managed to take the medicine as directed and use cardiovascular health from it,” said Dr. Darren McGuire, professor of medicine at UT Southwestern Medical Center and the first author of the study.
